IMMB News Out! Check it~~~~ Immunotech Announces Canadian

New Post Public Reply Private Reply Replies (0) Message Board
Godspeed

IMMB News Out! Check it~~~~>

Immunotech Announces Canadian Special Access Program Could Allow Legal Treatment of Company's Patented (IPF-ITV-1) AIDS-HIV T...

Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has entered negotiations with a Canadian Wellness Organization for the use of Immunotech's Patented AIDS-HIV Treatment.

Immunotech's Chief Scientific Officer commented, "Canada has a Special Access Program (SAP) for Experimental Drugs for Treatment of Life Threatening and Terminal Diseases, such as Immunotech's IPF-ITV AIDS-HIV Treatment."

The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radiopharmaceutical products and upon satisfactory due diligence and agreement of terms by both parties an agreement such as this could be expedited to implement the legal treatment of the IPF-ITV-1 Treatment in short order, which could result in helping save lives of terminal patients right away. The results from these patients could assist with the Clinical Trials for FDA approval in the United States.

Background on the Special Access Program

The SAP considers requests from practitioners for access to non-marketed drugs for treatment, diagnosis or prevention of serious or life-threatening conditions when conventional therapies have been considered and ruled out, have failed, are unsuitable, and/or unavailable. The regulatory authority supporting the program is discretionary and a decision to authorize or deny a request is made on a case-by-case basis by taking into consideration the nature of the medical emergency, the availability of marketed alternatives and the information provided in support of the request regarding the use, safety and efficacy of the drug. This authority however, does not extend to covering the cost of drugs and does not take into consideration the cost of marketed alternatives. If access is granted, the physician agrees to report on the use of the drug including any adverse events encountered with such use, and must account for all quantities received to both the SAP and the manufacturer.

The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada.

According to the CDC, millions of people worldwide are infected today with HIV/AIDS.

More than 34 million people now live with the HIV/AIDS Virus according to "amfAR" The Foundation for AIDS Research.

Link to SAP Program & Application:

www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index_e.html

RECENT ARTICLES & LINKS FOR RELATIVE AIDS-HIV MEDICINE & BABY HIV CURES

http://timesofindia.indiatimes.com//articlesh...ttarget=no

http://www.mccormick.northwestern.edu/news/ar...F-PI.email

http://www.amfar.org/about_hiv_and_aids/facts...worldwide/

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.


Company Contact:

Immunotech Laboratories, Inc.

Email Contact

Investor Relations:

The Nabors Group:

713-875-9200

E-mail: Email Contact

www.facebook.com/Naborsgroup

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 24

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 53

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 36

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Soitec's Current Share Capital and Voting Rights

Updated Category News Views 82

Understanding Soitec's Share Capital and Voting Rights For stakeholders in the corporate sector, grasping the concepts of share capital and voting rights is essential. Soitec, a prominent player in the semiconductor materials industry, has made notable strides and contributions in this field. Let’s explore the most recent updates regarding the total number of voting...

Continue Reading
Investing in Tomorrow: Why Future Industries Matter Today

Updated Category News Views 202

The Importance of Investing in Future Industries Many people today ponder the importance of investing in future industries, questioning why resources should be allocated to them when they seem distant from our everyday lives. This inquiry addresses a crucial topic with significant long-term implications. Future industries like quantum technology, nuclear fusion energy,...

Continue Reading
TIER IV Partners with JR Central to Transform Regional Mobility

Updated Category News Views 184

TIER IV and JR Central: A Partnership for the Future TIER IV, a leader in open-source software for autonomous driving, is embarking on an exciting journey by forming a strategic partnership with Central Japan Railway Company (JR Central). This collaboration aims to revolutionize regional transportation by integrating cutting-edge autonomous driving technology with rail...

Continue Reading
eMazzanti Technologies Shines with Four Microsoft Designations

Updated Category News Views 186

eMazzanti Technologies Celebrates Major Microsoft Partnership Success A Remarkable Achievement in the Tech Landscape eMazzanti Technologies, a well-regarded provider of IT services and cybersecurity solutions, proudly announces its attainment of four distinguished Solutions Partner designations in the Microsoft AI Cloud Partner Program. This accomplishment elevates the...

Continue Reading
Understanding the Current Trends in Wynn Resorts' Options Market

Updated Category News Views 200

Understanding Wynn Resorts' Trading Dynamics In a remarkable turn of events, significant investors have adopted a bullish outlook on Wynn Resorts WYNN. This new sentiment has implications for retail traders and analysts trying to gauge the company's future performance. Investor Sentiment: A Deep Dive Ricocheting through financial markets, the latest trades signaling...

Continue Reading